US20230213526A9 - Method for screening personalized intestinal environment-improving material and composition therefor - Google Patents
Method for screening personalized intestinal environment-improving material and composition therefor Download PDFInfo
- Publication number
- US20230213526A9 US20230213526A9 US17/645,451 US202117645451A US2023213526A9 US 20230213526 A9 US20230213526 A9 US 20230213526A9 US 202117645451 A US202117645451 A US 202117645451A US 2023213526 A9 US2023213526 A9 US 2023213526A9
- Authority
- US
- United States
- Prior art keywords
- screening
- intestinal environment
- microbiota
- pmas
- feces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 239000000463 material Substances 0.000 title claims abstract description 96
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000012216 screening Methods 0.000 title claims abstract description 58
- 238000004458 analytical method Methods 0.000 claims abstract description 69
- 241000736262 Microbiota Species 0.000 claims abstract description 50
- 239000006041 probiotic Substances 0.000 claims abstract description 34
- 235000018291 probiotics Nutrition 0.000 claims abstract description 34
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 25
- 239000002207 metabolite Substances 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 230000036541 health Effects 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 49
- 210000003608 fece Anatomy 0.000 claims description 46
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 46
- 241000894006 Bacteria Species 0.000 claims description 41
- 230000007423 decrease Effects 0.000 claims description 38
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 32
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 32
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 25
- 239000002158 endotoxin Substances 0.000 claims description 22
- 230000009286 beneficial effect Effects 0.000 claims description 19
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 13
- 239000004201 L-cysteine Substances 0.000 claims description 13
- 235000013878 L-cysteine Nutrition 0.000 claims description 13
- 229960002433 cysteine Drugs 0.000 claims description 13
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 7
- 244000005709 gut microbiome Species 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000012137 tryptone Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000010197 meta-analysis Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims 3
- 230000002588 toxic effect Effects 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 230000002550 fecal effect Effects 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229920000774 poly(2-methoxyaniline-5-sulfonic acid) polymer Polymers 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 230000008569 process Effects 0.000 description 29
- 230000000813 microbial effect Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 22
- 238000010586 diagram Methods 0.000 description 14
- 239000003440 toxic substance Substances 0.000 description 13
- 230000006872 improvement Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 102000015728 Mucins Human genes 0.000 description 11
- 108010063954 Mucins Proteins 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000028774 intestinal disease Diseases 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- -1 maltose and lactose Chemical class 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00818—Treatment of the gastro-intestinal system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Definitions
- the present disclosure relates to a composition for screening an intestinal environment-improving material and a screening method using the composition.
- Genome refers to the gene contained in the chromosome
- microbiota refers to the microbial community in the environment as a microbial flora
- microbiome refers to the genome of the total microbial community in the environment.
- the microbiome may mean a combination of the genome and the microbiota.
- Microbiota is known to play an important role in maintaining the homeostasis of the host, e.g., human immunity, metabolites and the like.
- the microbiota and the host transmit and receive chemical signals to and from each other, and the expression of immune cells, neurotransmitter production and short-chain fatty acids (SCFA) by the microbiota have a significant effect on the host system.
- SCFA short-chain fatty acids
- Probiotics/prebiotics balance the host's unbalanced microbiota so that a healthy metabolite of the microbiota boosts the host's health.
- Existing probiotics like generic drugs, give everyone the same dose and similar species.
- the present disclosure proposes a method for verifying the suitability of the individual microbiota of foods, health functional foods and drugs that promote the regulation and improvement of various microbiota including probiotics or prebiotics in a personalized manner.
- the present disclosure provides a composition for screening an intestinal environment-improving material, a screening method using the composition, and a method for providing information for diagnosing a disease by detection of an intestinal biomarker.
- the problems to be solved by the present disclosure are not limited to the above-described problems.
- other problems to be solved by the present disclosure can be clearly understood by a person with ordinary skill in the art from the following descriptions.
- a first aspect of the present disclosure provides a composition for screening an intestinal environment-improving material, including L-cysteine.
- a second aspect of the present disclosure provides a method for screening an intestinal environment-improving material, including: (a) mixing a composition of the first aspect with a sample obtained from a subject; (b) treating one or more intestinal environment-improving candidate materials in the mixture from the process (a) and culturing; and (c) analyzing the culture from the process (b).
- an effective analysis method for screening a microbiota-improving candidate material in a personalized manner by providing a method for verifying personalized probiotics, prebiotics, foods, health functional foods and drugs under in vitro conditions based on microbiota and microbiota metabolites.
- This method according to the present disclosure can be applied to a biomarker-based screening system and can quickly verify a personalized candidate material with an effective personalized screening method.
- FIG. 1 is an exemplary diagram illustrating a process for screening personalized probiotics, prebiotics, foods, health functional foods and drugs through the PMAS technique.
- FIG. 2 is an exemplary diagram provided to explain a sample analysis through the PMAS technique.
- FIG. 3 is an exemplary diagram provided to interpret a sample analysis result through the PMAS technique.
- FIG. 4 illustrates an example of screening personalized probiotics, prebiotics, food, health functional food and drug candidate materials based on an analysis result obtained after PMAS.
- FIG. 5 is a diagram showing an analysis result on the short-chain fatty acid content depending on the composition of a PMAS medium.
- FIG. 6 is a diagram showing an analysis result on the short-chain fatty acid content depending on the PMAS culture time.
- FIG. 7 is a diagram illustrating the reproducibility of the PMAS technique of the present disclosure.
- FIG. 8 is a diagram illustrating the identity between a clinical result and a result obtained by the PMAS technique of the present disclosure.
- FIG. 9 is an exemplary diagram illustrating the configuration of a plate well when PMAS of the present disclosure is performed.
- FIG. 10 is an exemplary diagram illustrating an analysis on a change in the amount of butyrate in a PMAS test of the present disclosure.
- FIG. 11 is an exemplary diagram illustrating an analysis on a change in microbial diversity in a PMAS test of the present disclosure.
- FIG. 12 A and FIG. 12 B are exemplary diagram illustrating an analysis on a correlation between microbial composition and butyrate.
- the term “comprises or includes” and/or “comprising or including” used in the document means that one or more other components, steps, operation and/or existence or addition of elements are not excluded in addition to the described components, steps, operation and/or elements unless context dictates otherwise.
- the term “about or approximately” or “substantially” is intended to have meanings close to numerical values or ranges specified with an allowable error and intended to prevent accurate or absolute numerical values disclosed for understanding of the present disclosure from being illegally or unfairly used by any unconscionable third party.
- a first aspect of the present disclosure provides a composition for screening an intestinal environment-improving material, including L-cysteine.
- the composition is prepared for screening a candidate material capable of improving an intestinal environment.
- a candidate material capable of improving an intestinal environment can be understood as a composition to be used in a series of processes of monitoring the progress of improvement in the intestinal environment and evaluating whether the candidate material can improve the intestinal environment, but is not particularly limited thereto.
- the composition is prepared for identically/similarly mimicking the intestinal environment of an individual user in vitro and makes is possible to accurately and efficiently check whether the candidate material can improve the intestinal environment under in vitro conditions and thus can be usefully used for screening a personalized intestinal environment-improving material.
- intestinal environment improvement refers to advantageously changing the composition of intestinal microbiota and metabolites of the microbiota.
- the intestinal environment improvement results in an increase in beneficial intestinal bacteria and metabolites of the beneficial bacteria and thus has effects such as vitamin synthesis, improvement of digestion and absorption, prevention of infection and immunopotentiation, and also results in a decrease in harmful bacteria and metabolites of the harmful bacteria and thus has effects such as decrease in intestinal decomposition, decrease in bacterial toxins and decrease in carcinogens.
- the intestinal environment improvement can prevent or treat intestinal diseases such as diarrhea, constipation and enteritis and also prevent or treat cancers, obesity, diabetes, and brain-related diseases.
- the intestinal environment improvement may include one or more selected from the group consisting of an increase in microbial diversity of microbiota, a decrease in endotoxin and hydrogen sulfide derived from intestinal microbiota, an increase in metabolites derived from beneficial microbiota, an increase or decrease in short-chain fatty acids, an increase in kind and number of beneficial bacteria and a decrease in kind and number of harmful bacteria, but may not be limited thereto.
- L-cysteine is one of amino acid supplements and plays an important role in metabolism as a constituent of glutathione in vivo and is also used to inhibit browning of fruit juices and oxidation of vitamin C.
- the L-cysteine may be contained at a concentration of from 0.001% (w/v) to 5% (w/v), preferably 0.005% (w/v) to 3% (w/v), more preferably 0.01% (w/v) to 1% (w/v), most preferably from 0.01% (w/v) to 0.1% (w/v), but may not be limited thereto.
- the L-cysteine may be included in the composition for screening an intestinal environment-improving material in the form of various types of formulations or salts, and specifically, the L-cysteine may be L-cysteine hydrochloride, but may not be limited thereto.
- the composition may further include mucin, but may not be limited thereto.
- mucin is a mucosubstance secreted by the mucous membrane and includes submandibular gland mucin and others such as gastric mucosal mucin and small intestine mucin.
- Mucins are glycoproteins and known as one of energy sources such as carbon sources and nitrogen sources that intestinal microbiota can actually use.
- the mucin may be contained at a concentration of from 0.01% (w/v) to 5% (w/v), preferably 0.05% (w/v) to 3% (w/v), more preferably 0.07% (w/v) to 2% (w/v), and most preferably from 0.1% (w/v) to 1% (w/v), but may not be limited thereto.
- the composition may not include any nutrient other than the mucin and specifically may not include a nitrogen source and/or carbon source such as protein and carbohydrate.
- the protein that serves as a carbon source and nitrogen source may include one or more of tryptone, peptone, and yeast extract, but may not be limited thereto.
- the protein may be tryptone.
- the carbohydrate that serves as a carbon source may include one or more of monosaccharides such as glucose, fructose and galactose and disaccharides such as maltose and lactose, but may not be limited thereto.
- the carbohydrate may be glucose.
- the composition may not include glucose and tryptone, but may not be limited thereto.
- the composition may include one or more selected from the group consisting of sodium chloride (NaCl), sodium carbonate (NaHCO 3 ), potassium chloride (KCl) and hemin.
- NaCl sodium chloride
- NaHCO 3 sodium carbonate
- KCl potassium chloride
- the sodium chloride may be contained at a concentration of from 10 mM to 100 mM
- the sodium carbonate may be contained at a concentration of from 10 mM to 100 mM
- the potassium chloride may be contained at a concentration of from 1 mM to 30 mM
- the hemin may be contained at a concentration of from 1 ⁇ 10 ⁇ 6 g/L to 1 ⁇ 10 ⁇ 4 g/L, but may not be limited thereto.
- the composition may be a culture medium composition, but may not be limited thereto.
- the intestinal environment-improving material may include one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods and drugs, but may not be limited thereto.
- probiotics refers to bacteria that exhibit a beneficial in vivo effect on the health of a host. Specifically, probiotics that can reach the intestine and grow in the intestinal mucosa produce lactic acid which acidifies the intestinal environment, and, thus, harmful bacteria that cannot survive in acidic conditions decrease in number and beneficial bacteria that can live well in acidic conditions increase in number, which makes the intestinal environment healthy.
- the probiotics may include Lactobacillus, Lactococcus, Enterococcus, Streptococcus, Bifidobacterium and the like, but may not be limited thereto.
- the probiotics may be prepared in the form of fermented milk, granules, powder or the like including these strains.
- prebiotics refers to substances that activate probiotics which are beneficial bacteria thereby inhibiting harmful intestinal bacteria and also create an intestinal environment where probiotics can live well. Also, the prebiotics serve as food to be decomposed and used as energy source for the production of probiotics and are saccharides that cannot be absorbed into the body and thus are not absorbed into the small intestine and reach the intestine where they serve as food for lactic acid bacteria and also cause a decrease in harmful bacteria.
- the composition may create an intestinal environment under in vitro conditions.
- a second aspect of the present disclosure provides a method for screening an intestinal environment-improving material, including: (a) mixing a composition of the first aspect with a sample obtained from a subject; (b) treating one or more intestinal environment-improving candidate materials in the mixture from the process (a) and culturing; and (c) analyzing the culture from the process (b).
- the features described above in respect of the first aspect of the present disclosure may equally apply to the method according to the second aspect of the present disclosure.
- the method may be a method for screening a material for preventing and treating diseases caused by intestinal disorders.
- the method can be understood as a series of processes of treating a sample obtained from a subject in need of intestinal environment improvement with a candidate material capable of improving the intestinal environment, monitoring the progress of improvement in the intestinal environment and evaluating whether the candidate material can improve the intestinal environment, but is not particularly limited thereto. Specifically, if the intestinal environment has been improved when the degree of improvement in the intestinal environment, the candidate material can be determined as an intestinal environment-improving material.
- the method may be performed under in vitro conditions.
- the term “subject” refers to any living organism which may have an intestinal disorder, may have a disease caused by an intestinal disorder or develop it or may be in need of intestinal environment improvement. Specific examples thereof may include, but not limited to, mammals such as mice, monkeys, cattle, pigs, minipigs, domestic animals and humans, birds, cultured fish, and the like.
- sample refers to a material derived from the subject and specifically may be cells, urine, feces, or the like, but may not be limited thereto as long as a material, such as microbiota, intestinal microbial metabolites, endotoxins, and short-chain fatty acids, present in the intestine can be detected therefrom.
- the method may include a process of preparing a sample, a process of pretreating the sample, a process of analyzing the sample and data, and a process of screening a personalized intestinal environment-improving material based on the derived data, but may not be limited thereto.
- the method may be a fast screening method that is faster than conventionally known microbiota analysis methods and intestinal environment analysis methods.
- the “fast” may mean specifically 12 hours to 48 hours and more specifically 18 hours to 24 hours, but may not be limited thereto.
- the culturing in the process (b) may be performed for 12 hours to 48 hours and specifically for 18 hours to 24 hours, but may not be limited thereto.
- the method may be performed under anaerobic conditions.
- the culturing in the process (b) of the method may be performed under anaerobic conditions.
- the intestinal environment-improving candidate material may include one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods and drugs, but may not be limited thereto.
- the analyzing of the culture in the process (c) is to analyze whether the intestinal environment has been improved or not. Specifically, the analyzing of the culture in the process (c) is to analyze the kind, content and/or concentration of one or more of an endotoxin, hydrogen sulfide as a product of abnormal intestinal fermentation, short-chain fatty acids (SCFAs) and microbiota-derived metabolites contained in the culture and to analyze a change in kind, content and/or concentration when the sample is treated with the candidate material.
- SCFAs short-chain fatty acids
- endotoxin is a toxic substance that can be found inside a bacterial cell and acts as an antigen composed of a complex of proteins, polysaccharides, and lipids.
- the endotoxin may include lipopolysaccharides (LPS), but may not limited thereto.
- LPS lipopolysaccharides
- the LPS may be specifically gram negative and pro-inflammatory.
- SCFA short-chain fatty acid
- the short-chain fatty acids may include one or more selected from the group consisting of formate, acetate, propionate, butyrate, isobutyrate, valerate and iso-valerate, but may not be limited thereto.
- the analyzing of the culture in the process (c) may be to analyze the kind, content, concentration and/or diversity change of bacteria contained in the microbiota of the culture, but may not be limited thereto.
- the microbiota may include beneficial intestinal bacteria and harmful intestinal bacteria.
- the beneficial intestinal bacteria may include, but not limited to, Lactobacillus and Bifidobacterium
- the harmful intestinal bacteria may include, but not limited to, Proteobacteria and Clostridium difficile.
- a method of analyzing the endotoxin, the hydrogen sulfide as a product of abnormal intestinal fermentation, the short-chain fatty acids (SCFAs), the microbiota-derived metabolites, the microbiota, and intestinal microbial diversity may employ various analysis methods, such as genetic analysis methods including absorbance analysis, chromatography analysis and next generation sequencing, and metagenomic analysis methods, that can be used by a person with ordinary skill in the art.
- SCFAs short-chain fatty acids
- the method may further include screening a candidate material that increases the content of the short-chain fatty acids, increases the kind and content of beneficial bacteria in the microbiota, decreases the contents of the endotoxin and the hydrogen sulfide or decreases the kind and content of harmful bacteria in the microbiota by comparison between the result of analysis from the process (c) and the result of analysis on a control group.
- control group refers to a sample or data without limitation as long as it can be compared in changes of the intestinal environment (kind, concentration and/or content of the short-chain fatty acids, microbiota, endotoxins, hydrogen sulfide and intestinal microbial metabolites) caused by treatment with an intestinal environment-improving candidate material.
- the control group may include a non-treated sample from a subject or a sample treated only with a control material such as vehicle, saline solution, DMSO or the like, but may not be limited thereto.
- the method includes identically/similarly mimicking the intestinal environment of an individual user including microbiota, temperature, humidity, and motion in vitro and analyzing a predetermined number or more of probiotics, prebiotics, foods, health functional foods and drugs in a parallel manner.
- a predetermined number or more of probiotics, prebiotics, foods, health functional foods and drugs in a parallel manner.
- the method may include performing in vitro pretreatment, treatment with a microbiota-improving candidate material, verification of functionality and mode of action of the candidate material to feces samples of human and various animals that can most easily represent the intestinal microbial environment in vivo and examining the taxonomic identification, microbial safety and microbial functionality of the microbiota resulting from the candidate material.
- a microbiota-improving candidate material verification of functionality and mode of action of the candidate material to feces samples of human and various animals that can most easily represent the intestinal microbial environment in vivo and examining the taxonomic identification, microbial safety and microbial functionality of the microbiota resulting from the candidate material.
- the method enables screening of personalized probiotics, prebiotics, foods, health functional foods and drugs using samples such as feces.
- PMAS Personalized Pharmaceutical Meta-Analysis Screening
- a third aspect of the present disclosure provides a method for providing information for diagnosing a disease caused by an intestinal disorder.
- the features described above in respect of the first aspect and the second aspect of the present disclosure may equally apply to the method according to the third aspect of the present disclosure.
- the method may include detecting a biomarker for diagnosing a disease caused by an intestinal disorder from the sample obtained from the subject, and the method may include a sample preparation process, a sample pretreatment process, a sample analysis process, a data analysis process, and a process of diagnosing a disease based on the derived data.
- the biomarker may be a substance detected in the intestine and specifically may include microbiota, endotoxins, hydrogen sulfide, intestinal microbial metabolites, short-chain fatty acids and the like, but may not be limited thereto.
- the present disclosure relates to a composition and a method for screening personalized probiotics, foods, health functional foods and drugs under in vitro conditions using samples such as an individual's feces.
- the screening system will be described as being referred to as Personalized Pharmaceutical Meta-Analysis Screening (PMAS).
- FIG. 1 is an exemplary diagram illustrating a process for screening personalized probiotics, prebiotics, foods, health functional foods and drugs through the PMAS technique. The overall process of a screening system of the present disclosure will be described below with reference to FIG. 1 .
- Feces of a human or animal and a PMAS medium were mixed at a ratio of 1:12 and homogenized using a stomacher. Then, a filter was used to filter out residues of the feces. Before probiotics, food, health functional food and drug candidate materials were treated, the feces-medium mixture was reduced in an anaerobic chamber for 4 hours.
- the same amount of the homogenized feces-medium mixture was dispensed to each of culture plates such as 96-well plates.
- the probiotics, food, health functional food and drug candidate materials to be treated were suspended in sterile 1 ⁇ PBS to be homogenized in concentration and amount and then dispensed to the respective plates where the feces-medium mixture was placed.
- the plates were cultured under anaerobic conditions with temperature, humidity and motion similar to those of the intestinal environment to ferment and culture the respective test groups.
- Each of the cultured test groups was centrifuged to separate the supernatant and the pellet. Then, metabolites, short-chain fatty acids, toxic substances and the like from the supernatant were analyzed and microbiota from the pellet were analyzed.
- FIG. 2 and FIG. 3 are exemplary diagrams showing the sample analysis process in the PMAS technique of Example 1.
- toxic substances such as hydrogen sulfide and bacteria LPS (endotoxins) and microbial metabolites such as short-chain fatty acids from the supernatant obtained by centrifugation of the cultured test groups are analyzed through absorbance analysis and chromatography analysis and a culture-independent analysis method is performed to the microbiota from the centrifuged pellet.
- the amount of change in hydrogen sulfide produced by the culturing is measured through a methylene blue method using N,N-dimethyl-p-phenylene-diamine and iron chloride (FeCl 3 ) and the level of endotoxins that is one of inflammation promoting factors is measured using an endotoxin assay kit.
- microbial metabolites such as short-chain fatty acids including acetate, propionate and butyrate can be analyzed through gas chromatography.
- Microbiota can be analyzed by genome-based analysis through metagenomic analysis such as real-time PCR in which all genomes are extracted from a sample and a bacteria-specific primer suggested in the GULDA method or next generation sequencing.
- the method according to the present disclosure makes it possible to screen a personalized microbiota-improving candidate material based on at least one of analysis on toxic substances, analysis on microbiota-derived metabolites including short-chain fatty acids and analysis on microbiota. Specifically, it is possible to find out a candidate material that decreases in the level of toxic substances through the analysis on toxic substances including endotoxins and hydrogen sulfide, check a change in a predetermined target short-chain fatty acid through the analysis on short-chain fatty acids, and check a change in microbiota before and after the candidate material treatment through the analysis on microbiota. Therefore, it is possible to screen a personalized microbiota-improving candidate material.
- FIG. 4 is an exemplary diagram showing a process of screening personalized probiotics, foods, health functional foods and drugs based on the result of sample analysis of Example 2.
- an increase or decrease in the production of toxic substances, a change in SCFA, an increase or decrease in harmful bacteria and beneficial bacteria are determined based on the result of analysis after the execution of PMAS to determine whether the treated candidate material can improve microbiota. If the supernatant does not remain above the minimum amount for analysis when centrifugation is performed after fermentation and culture, the amount of supernatant to be used for analysis is secured by repeating PMAS and culture. If the toxic substances increase and the total amount of short-chain fatty acids is out of the normal range and the harmful bacteria decrease significantly as compared with before the treatment, microbiota imbalance is considered to be induced by the treatment material. Thus, the treatment material is excluded from the screening.
- the present disclosure makes it possible to screen a personalized microbiota-improving candidate material based on at least one of analysis on toxic substances including endotoxins and hydrogen, analysis on microbiota-derived metabolites including short-chain fatty acids, analysis on harmful intestinal bacteria including Proteobacteria and Clostridium difficile , and analysis on beneficial intestinal bacteria including Lactobacillus and Bifidobacterium .
- the production of toxic substances does not increase significantly, the total amount of short-chain fatty acids is within the normal range, the harmful bacteria do not increase significantly and the beneficial bacteria do not decrease significantly or if the beneficial bacteria decrease significantly but the diversity of microbiota increases, it is possible to select a test group with the largest increase in the ratio of butyrate in the total short-chain fatty acids and perform screening for personalized probiotics, foods, health functional foods and drugs.
- the harmful bacteria do not increase significantly and the beneficial bacteria do not decrease significantly or if the beneficial bacteria decrease significantly but the diversity of microbiota increases and additional analysis on an intestinal-specific biomarker is needed, additional analysis on an increase or decrease and presence or absence of the specific biomarker is performed, and based on the result of analysis, it is possible to select a test group in which the specific biomarker is affected by PMAS treatment and perform screening for personalized probiotics, prebiotics, foods, health functional foods and drugs.
- Test Example 1 Checking of Medium Composition for PMAS Technique
- feces samples were mixed at a ratio of 1:12 (w/v) with media having various compositions shown in the following Table 1 and then homogenized using a stomacher.
- Test 2 Test 3
- Test 4 Test 5 Glucose ⁇ X ⁇ X X Tryptone ⁇ X X ⁇ X Mucin X X X X ⁇ L-cysteine X ⁇ ⁇ ⁇ ⁇ Hydrochloride
- the feces samples were dispensed to 96-well plates.
- Test 1 and Test 3 treated with prebiotics known to be fermented by intestinal microbiota and to produce short-chain fatty acids did not show a change in content of butyrate, propionate and acetate and Test 4 treated with prebiotics showed a decrease in content of butyrate, propionate and acetate ( FIG. 5 ).
- Test 2 and Test 5 treated with prebiotics showed an overall increase in content of short-chain fatty acids ( FIG. 5 ). Since the absolute amount (mM) of short-chain fatty acids detected was higher in Test 5 than in Test 2, Test 5 is easier to analyze. Therefore, tests to be described in the following Test Examples were performed using media having the composition of Test 5.
- the composition (Test 2) that contains L-cysteine without nutritive components and the composition (Test 5) that contains L-cysteine and mucin actually showed the predicted results of prebiotics treatment. Therefore, the intestinal environment can be similarly mimicked in vitro with a medium that contains L-cysteine or L-cysteine and mucin without carbohydrate such as glucose and protein such as tryptone, and, thus, it is possible to rapidly and accurately check a change in the intestinal environment caused by treatment with a candidate material.
- test was performed in the same manner as in Test Example 1 except that the culture time of anaerobic culture was set to 0 hour, 18 hours, 21 hours, 24 hours, 40 hours and 48 hours. After culturing, the contents of butyrate, propionate and acetate were measured.
- Test Example 3 Validation of Personalized Material Candidate Screening Method Using PMAS Technique
- feces samples were obtained from twenty four persons, and whether the content of short-chain fatty acids in the feces samples increased or decreased by treatment with probiotics A was analyzed using the PMAS technique of the present disclosure.
- PMAS result the result obtained by the PMAS technique
- the PMAS technique of the present disclosure makes it possible to achieve the reproducibility in the same subject even under in vitro conditions and obtain a result very similar to an actual clinical result. Therefore, it can be seen that the PMAS technique can mimic the intestinal environment very similarly and by using the PMAS technique, it is possible to rapidly and efficiently screen an intestinal environment-improving material very effective for each individual.
- the control group was prepared to determine the degree of improvement in the intestinal environment by comparing analysis values measured after a PMAS test.
- An antibiotic mixture (ABX) in the reference treatment was used as a negative control group for creating an environment where microbial activities in feces sharply decreases and Clostridium butyricum (CB, bacterial strains that autonomously produce butyrate) was used as a positive control group for creating an environment where butyrate influential in determining whether the intestinal environment has been improved increases apparently.
- CB Clostridium butyricum
- LB, EF, BF are candidate materials to be tested, and different numbers represent bacterial strains.
- a PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a change in amount of butyrate was analyzed. The result of analysis was as shown in FIG. 10 .
- each row in the heat map of FIG. 10 represents a feces sample, and dot represents the case of an increase and diagonal line represents the case of a decrease in amount of butyrate relative to a well of the control group (reference) after the execution of PMAS.
- candidate materials serving as test groups are Lactobacillus, Bifidobacteria, Enterococcus -based bacteria that cannot autonomously produce butyrate.
- candidate materials serving as test groups are Lactobacillus, Bifidobacteria, Enterococcus -based bacteria that cannot autonomously produce butyrate.
- some feces treated with such strains show an increase in butyrate (black arrow of FIG. 10 ).
- treatment with a specific candidate material in the PMAS environment induces a change in activity of other microorganisms in the samples (an increase in butyrate).
- a PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a change in intestinal microbial diversity in some of the samples was analyzed. The result of analysis was as shown in FIG. 11 .
- each row in the heat map of FIG. 11 represents a feces sample, and dot represents the case of an increase and diagonal line represents the case of a decrease in microbial diversity relative to a well of the control group (reference) after the execution of PMAS.
- a PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a correlation between microbial composition and a change in amount of butyrate after the PMAS test was analyzed. The result of analysis was as shown in FIG. 12 A and FIG. B.
- FIG. 12 A is a graph showing the results of change in butyrate in the feces samples treated with different candidate materials after the execution of PMAS (multivariate, ten results expect the reference control group) on the plane through PCA analysis (x-axis: PC1, y-axis: PC2, 90.36% of all data are represented and dots in the graph represent the respective feces samples) and the initial faecal microbiota PC1 in the category is a PC1 score obtained by expressing initial faecal microbiota in the feces before the execution of PMAS calculated in weighted UniFrac distance. Further, FIG.
- 12 B is a graph showing a correlation between PC1 that is a main component of the results of change in butyrate in the respective feces samples after the execution of PMAS and PC1 that is beta diversity of microbiota change in the respective feces samples before the execution of PMAS.
- the results of change in butyrate in the respective feces samples after the execution of PMAS has a significant correlation with “the results of microbial analysis before the execution of PMAS”. That is, it can be inferred that a different pattern of change in butyrate for each feces sample after the execution of PMAS is caused by the distribution and composition of different microorganisms present in each feces sample (the change in butyrate is not random).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
Abstract
The present disclosure relates to a composition for screening an intestinal environment-improving material and a screening method using the composition, and according to the composition and the method of the present disclosure, it is possible to provide an effective analysis method for screening a microbiota-improving candidate material in a personalized manner by providing a method for verifying personalized probiotics, prebiotics, foods, health functional foods and drugs under in vitro conditions based on microbiota and microbiota metabolites.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/932,626, filed Jul. 17, 2020, which is a continuation-in-part of PCT/KR2020/001485 filed Jan. 31, 2020, which claims priority benefit from Korean Patent Application No. 10-2019-0107146, filed Aug. 30, 2019, the entire contents of each of which are incorporated herein by reference.
- The present disclosure relates to a composition for screening an intestinal environment-improving material and a screening method using the composition.
- Genome refers to the gene contained in the chromosome, microbiota refers to the microbial community in the environment as a microbial flora, and microbiome refers to the genome of the total microbial community in the environment. Herein, the microbiome may mean a combination of the genome and the microbiota.
- Microbiota is known to play an important role in maintaining the homeostasis of the host, e.g., human immunity, metabolites and the like. The microbiota and the host transmit and receive chemical signals to and from each other, and the expression of immune cells, neurotransmitter production and short-chain fatty acids (SCFA) by the microbiota have a significant effect on the host system.
- Probiotics/prebiotics balance the host's unbalanced microbiota so that a healthy metabolite of the microbiota boosts the host's health. Existing probiotics, like generic drugs, give everyone the same dose and similar species.
- However, per-human microbiome similarity is less than 50%, and there is increasing recognition and research on the personalization of probiotics.
- Therefore, the present disclosure proposes a method for verifying the suitability of the individual microbiota of foods, health functional foods and drugs that promote the regulation and improvement of various microbiota including probiotics or prebiotics in a personalized manner.
- In view of the foregoing, the present disclosure provides a composition for screening an intestinal environment-improving material, a screening method using the composition, and a method for providing information for diagnosing a disease by detection of an intestinal biomarker. However, the problems to be solved by the present disclosure are not limited to the above-described problems. Although not described herein, other problems to be solved by the present disclosure can be clearly understood by a person with ordinary skill in the art from the following descriptions.
- A first aspect of the present disclosure provides a composition for screening an intestinal environment-improving material, including L-cysteine.
- A second aspect of the present disclosure provides a method for screening an intestinal environment-improving material, including: (a) mixing a composition of the first aspect with a sample obtained from a subject; (b) treating one or more intestinal environment-improving candidate materials in the mixture from the process (a) and culturing; and (c) analyzing the culture from the process (b).
- According to examples and embodiments of the present disclosure, it is possible to provide an effective analysis method for screening a microbiota-improving candidate material in a personalized manner by providing a method for verifying personalized probiotics, prebiotics, foods, health functional foods and drugs under in vitro conditions based on microbiota and microbiota metabolites.
- This method according to the present disclosure can be applied to a biomarker-based screening system and can quickly verify a personalized candidate material with an effective personalized screening method.
- In the detailed description that follows, embodiments are described as illustrations only since various changes and modifications will become apparent to a person with ordinary skill in the art from the following detailed description. The use of the same reference numbers in different figures indicates similar or identical items.
-
FIG. 1 is an exemplary diagram illustrating a process for screening personalized probiotics, prebiotics, foods, health functional foods and drugs through the PMAS technique. -
FIG. 2 is an exemplary diagram provided to explain a sample analysis through the PMAS technique. -
FIG. 3 is an exemplary diagram provided to interpret a sample analysis result through the PMAS technique. -
FIG. 4 illustrates an example of screening personalized probiotics, prebiotics, food, health functional food and drug candidate materials based on an analysis result obtained after PMAS. -
FIG. 5 is a diagram showing an analysis result on the short-chain fatty acid content depending on the composition of a PMAS medium. -
FIG. 6 is a diagram showing an analysis result on the short-chain fatty acid content depending on the PMAS culture time. -
FIG. 7 is a diagram illustrating the reproducibility of the PMAS technique of the present disclosure. -
FIG. 8 is a diagram illustrating the identity between a clinical result and a result obtained by the PMAS technique of the present disclosure. -
FIG. 9 is an exemplary diagram illustrating the configuration of a plate well when PMAS of the present disclosure is performed. -
FIG. 10 is an exemplary diagram illustrating an analysis on a change in the amount of butyrate in a PMAS test of the present disclosure. -
FIG. 11 is an exemplary diagram illustrating an analysis on a change in microbial diversity in a PMAS test of the present disclosure. -
FIG. 12A andFIG. 12B are exemplary diagram illustrating an analysis on a correlation between microbial composition and butyrate. - Through the whole document, the term “comprises or includes” and/or “comprising or including” used in the document means that one or more other components, steps, operation and/or existence or addition of elements are not excluded in addition to the described components, steps, operation and/or elements unless context dictates otherwise. Through the whole document, the term “about or approximately” or “substantially” is intended to have meanings close to numerical values or ranges specified with an allowable error and intended to prevent accurate or absolute numerical values disclosed for understanding of the present disclosure from being illegally or unfairly used by any unconscionable third party.
- Through the whole document, the term “combination(s) of” included in Markush type description means mixture or combination of one or more components, steps, operations and/or elements selected from a group consisting of components, steps, operation and/or elements described in Markush type and thereby means that the disclosure includes one or more components, steps, operations and/or elements selected from the Markush group.
- Through the whole document, a phrase in the form “A and/or B” means “A or B, or A and B”.
- Hereinafter, embodiments and examples of the present disclosure will be described in detail with reference to the accompanying drawings. However, the present disclosure may not be limited to the following embodiments, examples and drawings.
- A first aspect of the present disclosure provides a composition for screening an intestinal environment-improving material, including L-cysteine.
- In an embodiment of the present disclosure, the composition is prepared for screening a candidate material capable of improving an intestinal environment. Specifically, it can be understood as a composition to be used in a series of processes of monitoring the progress of improvement in the intestinal environment and evaluating whether the candidate material can improve the intestinal environment, but is not particularly limited thereto.
- In an embodiment of the present disclosure, the composition is prepared for identically/similarly mimicking the intestinal environment of an individual user in vitro and makes is possible to accurately and efficiently check whether the candidate material can improve the intestinal environment under in vitro conditions and thus can be usefully used for screening a personalized intestinal environment-improving material.
- Through the whole document, the term “intestinal environment improvement” refers to advantageously changing the composition of intestinal microbiota and metabolites of the microbiota. The intestinal environment improvement results in an increase in beneficial intestinal bacteria and metabolites of the beneficial bacteria and thus has effects such as vitamin synthesis, improvement of digestion and absorption, prevention of infection and immunopotentiation, and also results in a decrease in harmful bacteria and metabolites of the harmful bacteria and thus has effects such as decrease in intestinal decomposition, decrease in bacterial toxins and decrease in carcinogens. Also, the intestinal environment improvement can prevent or treat intestinal diseases such as diarrhea, constipation and enteritis and also prevent or treat cancers, obesity, diabetes, and brain-related diseases.
- In an embodiment of the present disclosure, the intestinal environment improvement may include one or more selected from the group consisting of an increase in microbial diversity of microbiota, a decrease in endotoxin and hydrogen sulfide derived from intestinal microbiota, an increase in metabolites derived from beneficial microbiota, an increase or decrease in short-chain fatty acids, an increase in kind and number of beneficial bacteria and a decrease in kind and number of harmful bacteria, but may not be limited thereto.
- Through the whole document, the term “L-cysteine” is one of amino acid supplements and plays an important role in metabolism as a constituent of glutathione in vivo and is also used to inhibit browning of fruit juices and oxidation of vitamin C.
- In an embodiment of the present disclosure, the L-cysteine may be contained at a concentration of from 0.001% (w/v) to 5% (w/v), preferably 0.005% (w/v) to 3% (w/v), more preferably 0.01% (w/v) to 1% (w/v), most preferably from 0.01% (w/v) to 0.1% (w/v), but may not be limited thereto.
- In an embodiment of the present disclosure, the L-cysteine may be included in the composition for screening an intestinal environment-improving material in the form of various types of formulations or salts, and specifically, the L-cysteine may be L-cysteine hydrochloride, but may not be limited thereto.
- In an embodiment of the present disclosure, the composition may further include mucin, but may not be limited thereto.
- Through the whole document, the term “mucin” is a mucosubstance secreted by the mucous membrane and includes submandibular gland mucin and others such as gastric mucosal mucin and small intestine mucin. Mucins are glycoproteins and known as one of energy sources such as carbon sources and nitrogen sources that intestinal microbiota can actually use.
- In an embodiment of the present disclosure, the mucin may be contained at a concentration of from 0.01% (w/v) to 5% (w/v), preferably 0.05% (w/v) to 3% (w/v), more preferably 0.07% (w/v) to 2% (w/v), and most preferably from 0.1% (w/v) to 1% (w/v), but may not be limited thereto.
- In an embodiment of the present disclosure, the composition may not include any nutrient other than the mucin and specifically may not include a nitrogen source and/or carbon source such as protein and carbohydrate.
- In an embodiment of the present disclosure, the protein that serves as a carbon source and nitrogen source may include one or more of tryptone, peptone, and yeast extract, but may not be limited thereto. Specifically, the protein may be tryptone.
- In an embodiment of the present disclosure, the carbohydrate that serves as a carbon source may include one or more of monosaccharides such as glucose, fructose and galactose and disaccharides such as maltose and lactose, but may not be limited thereto. Specifically, the carbohydrate may be glucose.
- In an embodiment of the present disclosure, the composition may not include glucose and tryptone, but may not be limited thereto.
- In an embodiment of the present disclosure, the composition may include one or more selected from the group consisting of sodium chloride (NaCl), sodium carbonate (NaHCO3), potassium chloride (KCl) and hemin. Specifically, the sodium chloride may be contained at a concentration of from 10 mM to 100 mM, the sodium carbonate may be contained at a concentration of from 10 mM to 100 mM, the potassium chloride may be contained at a concentration of from 1 mM to 30 mM, and the hemin may be contained at a concentration of from 1×10−6 g/L to 1×10−4 g/L, but may not be limited thereto.
- In an embodiment of the present disclosure, the composition may be a culture medium composition, but may not be limited thereto.
- In an embodiment of the present disclosure, the intestinal environment-improving material may include one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods and drugs, but may not be limited thereto.
- Through the whole document, the term “probiotics” refers to bacteria that exhibit a beneficial in vivo effect on the health of a host. Specifically, probiotics that can reach the intestine and grow in the intestinal mucosa produce lactic acid which acidifies the intestinal environment, and, thus, harmful bacteria that cannot survive in acidic conditions decrease in number and beneficial bacteria that can live well in acidic conditions increase in number, which makes the intestinal environment healthy. The probiotics may include Lactobacillus, Lactococcus, Enterococcus, Streptococcus, Bifidobacterium and the like, but may not be limited thereto. The probiotics may be prepared in the form of fermented milk, granules, powder or the like including these strains.
- Through the whole document, the term “prebiotics” refers to substances that activate probiotics which are beneficial bacteria thereby inhibiting harmful intestinal bacteria and also create an intestinal environment where probiotics can live well. Also, the prebiotics serve as food to be decomposed and used as energy source for the production of probiotics and are saccharides that cannot be absorbed into the body and thus are not absorbed into the small intestine and reach the intestine where they serve as food for lactic acid bacteria and also cause a decrease in harmful bacteria.
- In an embodiment of the present disclosure, the composition may create an intestinal environment under in vitro conditions.
- A second aspect of the present disclosure provides a method for screening an intestinal environment-improving material, including: (a) mixing a composition of the first aspect with a sample obtained from a subject; (b) treating one or more intestinal environment-improving candidate materials in the mixture from the process (a) and culturing; and (c) analyzing the culture from the process (b). The features described above in respect of the first aspect of the present disclosure may equally apply to the method according to the second aspect of the present disclosure.
- In an embodiment of the present disclosure, the method may be a method for screening a material for preventing and treating diseases caused by intestinal disorders.
- In an embodiment of the present disclosure, the method can be understood as a series of processes of treating a sample obtained from a subject in need of intestinal environment improvement with a candidate material capable of improving the intestinal environment, monitoring the progress of improvement in the intestinal environment and evaluating whether the candidate material can improve the intestinal environment, but is not particularly limited thereto. Specifically, if the intestinal environment has been improved when the degree of improvement in the intestinal environment, the candidate material can be determined as an intestinal environment-improving material.
- In an embodiment of the present disclosure, the method may be performed under in vitro conditions.
- Through the whole document, the term “subject” refers to any living organism which may have an intestinal disorder, may have a disease caused by an intestinal disorder or develop it or may be in need of intestinal environment improvement. Specific examples thereof may include, but not limited to, mammals such as mice, monkeys, cattle, pigs, minipigs, domestic animals and humans, birds, cultured fish, and the like.
- Through the whole document, the term “sample” refers to a material derived from the subject and specifically may be cells, urine, feces, or the like, but may not be limited thereto as long as a material, such as microbiota, intestinal microbial metabolites, endotoxins, and short-chain fatty acids, present in the intestine can be detected therefrom.
- In an embodiment of the present disclosure, the method may include a process of preparing a sample, a process of pretreating the sample, a process of analyzing the sample and data, and a process of screening a personalized intestinal environment-improving material based on the derived data, but may not be limited thereto.
- In an embodiment of the present disclosure, the method may be a fast screening method that is faster than conventionally known microbiota analysis methods and intestinal environment analysis methods. The “fast” may mean specifically 12 hours to 48 hours and more specifically 18 hours to 24 hours, but may not be limited thereto.
- In an embodiment of the present disclosure, the culturing in the process (b) may be performed for 12 hours to 48 hours and specifically for 18 hours to 24 hours, but may not be limited thereto.
- In an embodiment of the present disclosure, the method may be performed under anaerobic conditions. Specifically, the culturing in the process (b) of the method may be performed under anaerobic conditions.
- In an embodiment of the present disclosure, the intestinal environment-improving candidate material may include one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods and drugs, but may not be limited thereto.
- In an embodiment of the present disclosure, the analyzing of the culture in the process (c) is to analyze whether the intestinal environment has been improved or not. Specifically, the analyzing of the culture in the process (c) is to analyze the kind, content and/or concentration of one or more of an endotoxin, hydrogen sulfide as a product of abnormal intestinal fermentation, short-chain fatty acids (SCFAs) and microbiota-derived metabolites contained in the culture and to analyze a change in kind, content and/or concentration when the sample is treated with the candidate material.
- Through the whole document, the term “endotoxin” is a toxic substance that can be found inside a bacterial cell and acts as an antigen composed of a complex of proteins, polysaccharides, and lipids.
- In an embodiment of the present disclosure, the endotoxin may include lipopolysaccharides (LPS), but may not limited thereto. The LPS may be specifically gram negative and pro-inflammatory.
- Through the whole document, the term, “short-chain fatty acid (SCFA)” refers to a short-length fatty acid with six or fewer carbon atoms and is a representative metabolite produced from intestinal microbiota. The SCFA has useful functions in the body, such as an increase in immunity, stabilization of intestinal lymphocytes, a decrease in insulin signaling, and stimulation of sympathetic nerves.
- In an embodiment of the present disclosure, the short-chain fatty acids may include one or more selected from the group consisting of formate, acetate, propionate, butyrate, isobutyrate, valerate and iso-valerate, but may not be limited thereto.
- In an embodiment of the present disclosure, the analyzing of the culture in the process (c) may be to analyze the kind, content, concentration and/or diversity change of bacteria contained in the microbiota of the culture, but may not be limited thereto.
- In an embodiment of the present disclosure, the microbiota may include beneficial intestinal bacteria and harmful intestinal bacteria. Specifically, the beneficial intestinal bacteria may include, but not limited to, Lactobacillus and Bifidobacterium, and the harmful intestinal bacteria may include, but not limited to, Proteobacteria and Clostridium difficile.
- In an embodiment of the present disclosure, a method of analyzing the endotoxin, the hydrogen sulfide as a product of abnormal intestinal fermentation, the short-chain fatty acids (SCFAs), the microbiota-derived metabolites, the microbiota, and intestinal microbial diversity may employ various analysis methods, such as genetic analysis methods including absorbance analysis, chromatography analysis and next generation sequencing, and metagenomic analysis methods, that can be used by a person with ordinary skill in the art.
- In an embodiment of the present disclosure, the method may further include screening a candidate material that increases the content of the short-chain fatty acids, increases the kind and content of beneficial bacteria in the microbiota, decreases the contents of the endotoxin and the hydrogen sulfide or decreases the kind and content of harmful bacteria in the microbiota by comparison between the result of analysis from the process (c) and the result of analysis on a control group.
- Through the whole document, the term “control group” refers to a sample or data without limitation as long as it can be compared in changes of the intestinal environment (kind, concentration and/or content of the short-chain fatty acids, microbiota, endotoxins, hydrogen sulfide and intestinal microbial metabolites) caused by treatment with an intestinal environment-improving candidate material. Specifically, the control group may include a non-treated sample from a subject or a sample treated only with a control material such as vehicle, saline solution, DMSO or the like, but may not be limited thereto.
- In an embodiment of the present disclosure, the method includes identically/similarly mimicking the intestinal environment of an individual user including microbiota, temperature, humidity, and motion in vitro and analyzing a predetermined number or more of probiotics, prebiotics, foods, health functional foods and drugs in a parallel manner. Thus, it is possible to rapidly screen the most effective personalized microbiota-improving candidate material.
- In an embodiment of the present disclosure, the method may include performing in vitro pretreatment, treatment with a microbiota-improving candidate material, verification of functionality and mode of action of the candidate material to feces samples of human and various animals that can most easily represent the intestinal microbial environment in vivo and examining the taxonomic identification, microbial safety and microbial functionality of the microbiota resulting from the candidate material. As such, through the fast screening method containing an individual's feces and special media and the analysis on feces-derived microbiome and metabolites, it is possible to efficiently screen personalized probiotics, prebiotics, foods, health functional foods and drugs.
- In an embodiment of the present disclosure, the method enables screening of personalized probiotics, prebiotics, foods, health functional foods and drugs using samples such as feces. Hereinafter, the method according to the present disclosure will be described as being referred to as Personalized Pharmaceutical Meta-Analysis Screening (PMAS).
- A third aspect of the present disclosure provides a method for providing information for diagnosing a disease caused by an intestinal disorder. The features described above in respect of the first aspect and the second aspect of the present disclosure may equally apply to the method according to the third aspect of the present disclosure.
- In an embodiment of the present disclosure, the method may include detecting a biomarker for diagnosing a disease caused by an intestinal disorder from the sample obtained from the subject, and the method may include a sample preparation process, a sample pretreatment process, a sample analysis process, a data analysis process, and a process of diagnosing a disease based on the derived data.
- In an embodiment of the present disclosure, the biomarker may be a substance detected in the intestine and specifically may include microbiota, endotoxins, hydrogen sulfide, intestinal microbial metabolites, short-chain fatty acids and the like, but may not be limited thereto.
- Hereinafter, examples of the present disclosure will be described in detail. However, the present disclosure may not be limited thereto.
- The present disclosure relates to a composition and a method for screening personalized probiotics, foods, health functional foods and drugs under in vitro conditions using samples such as an individual's feces. In the present disclosure, the screening system will be described as being referred to as Personalized Pharmaceutical Meta-Analysis Screening (PMAS).
-
FIG. 1 is an exemplary diagram illustrating a process for screening personalized probiotics, prebiotics, foods, health functional foods and drugs through the PMAS technique. The overall process of a screening system of the present disclosure will be described below with reference toFIG. 1 . - (1) Sample Preparation
- Feces of a human or animal and a PMAS medium were mixed at a ratio of 1:12 and homogenized using a stomacher. Then, a filter was used to filter out residues of the feces. Before probiotics, food, health functional food and drug candidate materials were treated, the feces-medium mixture was reduced in an anaerobic chamber for 4 hours.
- (2) Dispensing of Feces-Medium Mixture
- In the anaerobic chamber, the same amount of the homogenized feces-medium mixture was dispensed to each of culture plates such as 96-well plates.
- (3) Material Candidate Treatment
- The probiotics, food, health functional food and drug candidate materials to be treated were suspended in sterile 1×PBS to be homogenized in concentration and amount and then dispensed to the respective plates where the feces-medium mixture was placed.
- (4) Anaerobic Culture
- The plates were cultured under anaerobic conditions with temperature, humidity and motion similar to those of the intestinal environment to ferment and culture the respective test groups.
- (5) Sample Analysis
- Each of the cultured test groups was centrifuged to separate the supernatant and the pellet. Then, metabolites, short-chain fatty acids, toxic substances and the like from the supernatant were analyzed and microbiota from the pellet were analyzed.
-
FIG. 2 andFIG. 3 are exemplary diagrams showing the sample analysis process in the PMAS technique of Example 1. - Specifically, after the culture of the test groups treated with the candidate materials is ended, toxic substances such as hydrogen sulfide and bacteria LPS (endotoxins) and microbial metabolites such as short-chain fatty acids from the supernatant obtained by centrifugation of the cultured test groups are analyzed through absorbance analysis and chromatography analysis and a culture-independent analysis method is performed to the microbiota from the centrifuged pellet. For example, the amount of change in hydrogen sulfide produced by the culturing is measured through a methylene blue method using N,N-dimethyl-p-phenylene-diamine and iron chloride (FeCl3) and the level of endotoxins that is one of inflammation promoting factors is measured using an endotoxin assay kit. Also, microbial metabolites such as short-chain fatty acids including acetate, propionate and butyrate can be analyzed through gas chromatography. Microbiota can be analyzed by genome-based analysis through metagenomic analysis such as real-time PCR in which all genomes are extracted from a sample and a bacteria-specific primer suggested in the GULDA method or next generation sequencing. That is, the method according to the present disclosure makes it possible to screen a personalized microbiota-improving candidate material based on at least one of analysis on toxic substances, analysis on microbiota-derived metabolites including short-chain fatty acids and analysis on microbiota. Specifically, it is possible to find out a candidate material that decreases in the level of toxic substances through the analysis on toxic substances including endotoxins and hydrogen sulfide, check a change in a predetermined target short-chain fatty acid through the analysis on short-chain fatty acids, and check a change in microbiota before and after the candidate material treatment through the analysis on microbiota. Therefore, it is possible to screen a personalized microbiota-improving candidate material.
-
FIG. 4 is an exemplary diagram showing a process of screening personalized probiotics, foods, health functional foods and drugs based on the result of sample analysis of Example 2. - Specifically, an increase or decrease in the production of toxic substances, a change in SCFA, an increase or decrease in harmful bacteria and beneficial bacteria are determined based on the result of analysis after the execution of PMAS to determine whether the treated candidate material can improve microbiota. If the supernatant does not remain above the minimum amount for analysis when centrifugation is performed after fermentation and culture, the amount of supernatant to be used for analysis is secured by repeating PMAS and culture. If the toxic substances increase and the total amount of short-chain fatty acids is out of the normal range and the harmful bacteria decrease significantly as compared with before the treatment, microbiota imbalance is considered to be induced by the treatment material. Thus, the treatment material is excluded from the screening. However, if the number of beneficial bacteria decreases, it is excluded from the screening only when the diversity of all microbiota examined through metagenomic analysis using next generation sequencing decreases significantly. In addition, to perform screening with reference to the effects of probiotics, food, health functional food and drug candidate materials on a specific intestinal biomarker, analysis on the biomarker is performed for screening only when the candidate materials pass the above-mentioned screening criteria.
- That is, the present disclosure makes it possible to screen a personalized microbiota-improving candidate material based on at least one of analysis on toxic substances including endotoxins and hydrogen, analysis on microbiota-derived metabolites including short-chain fatty acids, analysis on harmful intestinal bacteria including Proteobacteria and Clostridium difficile, and analysis on beneficial intestinal bacteria including Lactobacillus and Bifidobacterium. Specifically, it is possible to find out a candidate material that decreases in the level of toxic substances through the analysis on toxic substances including endotoxins and hydrogen sulfide, check a change in a predetermined target short-chain fatty acid through the analysis on short-chain fatty acids, and check an increase or decrease in harmful intestinal bacteria and beneficial intestinal bacteria through the analysis on harmful intestinal bacteria and the analysis on harmful intestinal bacteria. Therefore, it is possible to screen a personalized microbiota-improving candidate material. For example, if the production of toxic substances does not increase significantly, the total amount of short-chain fatty acids is within the normal range, the harmful bacteria do not increase significantly and the beneficial bacteria do not decrease significantly or if the beneficial bacteria decrease significantly but the diversity of microbiota increases, it is possible to select a test group with the largest increase in the ratio of butyrate in the total short-chain fatty acids and perform screening for personalized probiotics, foods, health functional foods and drugs. If the production of toxic substances does not increase significantly, the total amount of short-chain fatty acids is within the normal range, the harmful bacteria do not increase significantly and the beneficial bacteria do not decrease significantly or if the beneficial bacteria decrease significantly but the diversity of microbiota increases and additional analysis on an intestinal-specific biomarker is needed, additional analysis on an increase or decrease and presence or absence of the specific biomarker is performed, and based on the result of analysis, it is possible to select a test group in which the specific biomarker is affected by PMAS treatment and perform screening for personalized probiotics, prebiotics, foods, health functional foods and drugs.
- To check the optimal composition of a PMAS medium for the PMAS technique of Example 1, a test was performed as follows.
- Specifically, feces samples were mixed at a ratio of 1:12 (w/v) with media having various compositions shown in the following Table 1 and then homogenized using a stomacher.
-
TABLE 1 Test 1Test 2Test 3Test 4Test 5Glucose ◯ X ◯ X X Tryptone ◯ X X ◯ X Mucin X X X X ◯ L-cysteine X ◯ ◯ ◯ ◯ Hydrochloride - Then, the feces samples were dispensed to 96-well plates. The control group was treated with no material and the prebiotics groups were treated with a prebiotic agent (medium: feces sample:prebiotics=1:12:2 (w/v)) and then cultured under anaerobic conditions at 37° C. for 18 hours. Then, the control group was compared with the prebiotics groups in terms of the contents of butyrate, propionate and acetate.
- As a result, it was verified that
Test 1 andTest 3 treated with prebiotics known to be fermented by intestinal microbiota and to produce short-chain fatty acids did not show a change in content of butyrate, propionate and acetate andTest 4 treated with prebiotics showed a decrease in content of butyrate, propionate and acetate (FIG. 5 ). - On the other hand, it was verified that
Test 2 andTest 5 treated with prebiotics showed an overall increase in content of short-chain fatty acids (FIG. 5 ). Since the absolute amount (mM) of short-chain fatty acids detected was higher inTest 5 than inTest 2,Test 5 is easier to analyze. Therefore, tests to be described in the following Test Examples were performed using media having the composition ofTest 5. - According to the above-described results, it can be seen that the composition (Test 2) that contains L-cysteine without nutritive components and the composition (Test 5) that contains L-cysteine and mucin actually showed the predicted results of prebiotics treatment. Therefore, the intestinal environment can be similarly mimicked in vitro with a medium that contains L-cysteine or L-cysteine and mucin without carbohydrate such as glucose and protein such as tryptone, and, thus, it is possible to rapidly and accurately check a change in the intestinal environment caused by treatment with a candidate material.
- To check the optimal culture time for anaerobic culture in the PMAS technique of Example 1, a test was performed as follows.
- Specifically, the test was performed in the same manner as in Test Example 1 except that the culture time of anaerobic culture was set to 0 hour, 18 hours, 21 hours, 24 hours, 40 hours and 48 hours. After culturing, the contents of butyrate, propionate and acetate were measured.
- As a result, it was verified that both the control group and the prebiotics groups showed a sharp increase in content of short-chain fatty acids up to the culture time of 18 hours and then entered a plateau phase (
FIG. 6 ). - According to the above-described results, it can be seen that when the culture time for anaerobic culture is set to 18 hours, it is the most efficient for fast screening of a candidate material using the PMAS technique of the present disclosure.
- To verify whether it is possible to accurately screen a personalized candidate material in an individual's intestinal environment created in vitro by using the PMAS technique of the present disclosure, tests were performed as follows.
- (1) Verification of Reproducibility
- To verify whether the result of analysis using the PMAS technique of the present disclosure is reproduced in the same subject, a test was performed as follows.
- Specifically, to verify the reproducibility of PMAS analysis result in feces samples A1 to A4 and B1 to B3 collected on respective dates from different persons A and B, the amount of butyrate was measured from the control group treated with no material and the test groups treated with five candidate materials and the butyrate quantitative values of the test groups treated with five candidate materials were divided by the butyrate quantitative value of the control group to find out the amounts of butyrate increased or decreased when the samples were treated with the materials candidates, respectively. Then, all the results of treatment of the respective samples with the five candidate materials were analyzed using the Pearson correlation (as the correlation coefficient gets closer to 1, it indicates a higher similarity).
- As a result, the results of PMAS analysis on the feces samples collected from the same person showed a considerably similar trend (correlation coefficient of 0.8 or more) but differences from the results of PMAS analysis on the feces samples collected from the different person (
FIG. 7 ). According to the above-described results, it can be seen that the result of analysis using the PMAS technique of the present disclosure is reproduced in the samples of the same person even under in vitro conditions. - (2) Verification of Identity with Clinical Result
- To verify whether the result of analysis using the PMAS technique of the present disclosure shows identity with an actual clinical result, a test was performed as follows.
- Specifically, feces samples were obtained from twenty four persons, and whether the content of short-chain fatty acids in the feces samples increased or decreased by treatment with probiotics A was analyzed using the PMAS technique of the present disclosure.
- Then, after the same twenty four persons actually took the probiotics A, whether the content of short-chain fatty acids changed between feces samples obtained before and after intake was clinically checked, and the clinical result was compared with the result obtained by the PMAS technique (hereinafter, referred to as “PMAS result”).
- As a result, it was actually verified that twelve out of twelve persons showed an increase in short-chain fatty acids in their feces after intake of the probiotics A and the other twelve persons showed a decrease in short-chain fatty acids. Also, according to the result of verifying the effects of the probiotics A using the PMAS technique, short-chain fatty acids increased in the samples from a total of fourteen persons and decreased in the samples from ten persons (
FIG. 8 ). Analysis was performed based on the above-described results as follows. - 1) Cases of an actual increase in short-chain fatty acids when short-chain fatty acids increased according to the PMAS result—11/14=0.79
- 2) Cases of an actual decrease in short-chain fatty acids when short-chain fatty acids decreased according to the PMAS result—9/10=0.9
- 3) Cases of an increase in short-chain fatty acids according to the PMAS result among the persons whose short-chain fatty acids actually increased—11/12=0.92
- 4) Cases of a decrease in short-chain fatty acids according to the PMAS result among the persons whose short-chain fatty acids actually decreased—9/12=0.75
- 5) False negative to an increase in short-chain fatty acids—1−0.92=0.08
- 6) False positive to an increase in short-chain fatty acids—1−0.75=0.25
- 7) Assuming prevalence (frequency at which short-chain fatty acids increase after actual intake of the probiotics A) is 0.5, PPV=(0.92×0.5)/(0.92×0.5+(1−0.75)×(1−0.5))=0.79
- According to the above-described results, the PMAS technique of the present disclosure makes it possible to achieve the reproducibility in the same subject even under in vitro conditions and obtain a result very similar to an actual clinical result. Therefore, it can be seen that the PMAS technique can mimic the intestinal environment very similarly and by using the PMAS technique, it is possible to rapidly and efficiently screen an intestinal environment-improving material very effective for each individual.
- By using the PMAS technique described above in Examples 1 to 3 and Test Examples 1 to 3, it is possible to rapidly and accurately analyze an individual's intestinal environment under in vitro conditions as described below and based on the result of analysis, it is possible to screen a candidate material capable of improving the intestinal environment. The following description is an example of a screening system using the PMAS technique, and it would be understood by a person with ordinary skill in the art that various changes and modifications can be made from the above description. For example, suitable results may be achieved if the described techniques are performed in a different order and/or if components in the described system, architecture, device, or process are combined in a different manner or replaced or substituted by other components or their equivalent.
- (1) Preparation of Feces-Medium Mixture and Material Candidate Treatment Each of feces samples obtained from eight persons was mixed with a PMAS medium and homogenized and then the same amount of the homogenized feces-medium mixture was dispensed to each of 96-well plates (horizontal axis), and the 96-well plates to which the feces samples were dispensed were vertically treated with different candidate materials (
FIG. 9 ). - The control group (reference) was prepared to determine the degree of improvement in the intestinal environment by comparing analysis values measured after a PMAS test. An antibiotic mixture (ABX) in the reference treatment was used as a negative control group for creating an environment where microbial activities in feces sharply decreases and Clostridium butyricum (CB, bacterial strains that autonomously produce butyrate) was used as a positive control group for creating an environment where butyrate influential in determining whether the intestinal environment has been improved increases apparently. Also, other bacterial strains LB, EF, BF are candidate materials to be tested, and different numbers represent bacterial strains.
- (2) PMAS Analysis Result—Analysis on Change in Amount of Butyrate
- A PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a change in amount of butyrate was analyzed. The result of analysis was as shown in
FIG. 10 . - Specifically, each row in the heat map of
FIG. 10 represents a feces sample, and dot represents the case of an increase and diagonal line represents the case of a decrease in amount of butyrate relative to a well of the control group (reference) after the execution of PMAS. - As a result, it can be seen that butyrate increases significantly in the case of treatment with CB which is a butyrate positive control group as compared with other treatments and butyrate decreases significantly in the case of treatment with ABX which is a negative control group as compared with other treatments (a decrease in microbial metabolite-butyrate caused by a decrease in microbial activities).
- Further, candidate materials serving as test groups are Lactobacillus, Bifidobacteria, Enterococcus-based bacteria that cannot autonomously produce butyrate. However, it can be seen that some feces treated with such strains show an increase in butyrate (black arrow of
FIG. 10 ). Accordingly, in some cases (some feces samples), it can be inferred that treatment with a specific candidate material in the PMAS environment induces a change in activity of other microorganisms in the samples (an increase in butyrate). - According to the above-described results, it can be seen that an environmental change caused by treatment with a candidate material in the PMAS technique is different for each feces sample. Accordingly, it can be seen that it is possible to screen an intestinal environment-improving candidate material based on microorganisms in each feces sample.
- (3) PMAS Analysis Result—Change in Intestinal Microbial Diversity
- A PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a change in intestinal microbial diversity in some of the samples was analyzed. The result of analysis was as shown in
FIG. 11 . - Specifically, each row in the heat map of
FIG. 11 represents a feces sample, and dot represents the case of an increase and diagonal line represents the case of a decrease in microbial diversity relative to a well of the control group (reference) after the execution of PMAS. - As a result, it can be seen that a candidate material for increasing or decreasing the microbial diversity is different for each feces sample. Further, it was verified that an effect of each candidate material is expressed differently for each feces sample. Furthermore, it was verified that the microbial diversity decreases significantly in the case of treatment with ABX as compared with other treatment groups.
- (4) PMAS Analysis Result—Correlation Between Microbial Composition of Initial Feces Sample and Change in Amount of Butyrate after PMAS Test
- A PMAS test was performed using feces samples obtained from 100 adult persons in the same manner as described above in paragraph (1), and a correlation between microbial composition and a change in amount of butyrate after the PMAS test was analyzed. The result of analysis was as shown in
FIG. 12A and FIG. B. - Specifically,
FIG. 12A is a graph showing the results of change in butyrate in the feces samples treated with different candidate materials after the execution of PMAS (multivariate, ten results expect the reference control group) on the plane through PCA analysis (x-axis: PC1, y-axis: PC2, 90.36% of all data are represented and dots in the graph represent the respective feces samples) and the initial faecal microbiota PC1 in the category is a PC1 score obtained by expressing initial faecal microbiota in the feces before the execution of PMAS calculated in weighted UniFrac distance. Further,FIG. 12B is a graph showing a correlation between PC1 that is a main component of the results of change in butyrate in the respective feces samples after the execution of PMAS and PC1 that is beta diversity of microbiota change in the respective feces samples before the execution of PMAS. - According to the above-described results, it can be seen that “the results of change in butyrate in the respective feces samples after the execution of PMAS” has a significant correlation with “the results of microbial analysis before the execution of PMAS”. That is, it can be inferred that a different pattern of change in butyrate for each feces sample after the execution of PMAS is caused by the distribution and composition of different microorganisms present in each feces sample (the change in butyrate is not random).
- The above description of the present disclosure is provided for the purpose of illustration, and it would be understood by a person with ordinary skill in the art that various changes and modifications may be made without changing technical conception and essential features of the present disclosure. Thus, it is clear that the above-described examples are illustrative in all aspects and do not limit the present disclosure. For example, each component described to be of a single type can be implemented in a distributed manner. Likewise, components described to be distributed can be implemented in a combined manner.
- The scope of the present disclosure is defined by the following claims rather than by the detailed description of the embodiment. It shall be understood that all modifications and embodiments conceived from the meaning and scope of the claims and their equivalents are included in the scope of the present disclosure.
Claims (19)
1. A method for screening an intestinal environment-improving material, comprising:
(a) mixing a composition for screening an intestinal environment-improving material with a sample obtained from a subject;
(b) treating the mixture from step (a) with one or more intestinal environment-improving candidate materials and culturing the mixture; and
(c) analyzing the culture from step (b) to analyze toxin, intestinal microbiota, microbiota-derived metabolite, or a mixture thereof in the culture to determine content or concentration thereof,
wherein
the composition for screening an intestinal environment-improving material does not include protein and carbohydrate.
2. The method of claim 1 , wherein the composition for screening an intestinal environment-improving material comprises L-cysteine.
3. The method of claim 1 , wherein the composition for screening an intestinal environment-improving material comprises L-cysteine and mucin.
4. The method of claim 1 , wherein the intestinal environment-improving material is selected from the group consisting of probiotic, prebiotic, food, health functional food, drug and a mixture thereof.
5. The method of claim 1 , wherein the toxin is endotoxin or hydrogen sulfide.
6. The method of claim 1 , wherein the microbiota-derived metabolite is a short-chain fatty acid (SCFA).
7. The method of claim 6 , wherein the short-chain fatty acid is selected from the group consisting of acetate, propionate, butyrate, isobutyrate, valerate and iso-valerate.
8. The method of claim 1 , wherein the method is performed under in vitro conditions.
9. The method of claim 1 , wherein the culturing in step (b) is performed under an anaerobic condition for 18 hours to 48 hours.
10. The method of claim 1 , wherein the analyzing the culture in the step (c) is to analyze the content, concentration, or type of toxin.
11. The method of claim 1 , wherein the analyzing the culture in the step (c) is to analyze the kind, concentrate, content or diversity change of intestinal microbiota contained in the culture.
12. A method for screening an intestinal environment-improving material of claim 1 , further comprising:
(d) screening a candidate material that increases the content of the short-chain fatty acids, increases the kind and content of beneficial bacteria in the microbiota, decreases the contents of endotoxin and hydrogen sulfide or decreases the kind and content of harmful bacteria in the microbiota by comparison between the result of analysis from the step (c) and the result of analysis on a control group.
13. A method for screening an intestinal environment-improving material, comprising:
(1) preparing a mixture of human or animal feces and a Pharmaceutical Meta-Analysis Screening (PMAS) medium;
(2) Dispensing identical quantities of the feces-PMAS medium mixture into culture plates in an anaerobic chamber;
(3) screening each candidate intestinal environment-improving material;
(4) culturing the prepared plates under anaerobic conditions with temperature, humidity and motion similar to those of the intestinal environment to ferment and culture the respective test groups; and
(5) centrifuging the culture products of step (4) to obtain supernatant; and
(6) testing for the presence of toxic or undesirable substances.
14. The method of claim 13 , wherein step (1) comprises the following steps:
(a) obtaining feces of a human or animal and mixing the feces with a PMAS medium,
(b) homogenizing the mixture using a stomacher;
(c) filtering fecal residues from the feces; and
(d) reducing the feces-medium mixture in an anaerobic chamber.
15. The method of claim 13 , wherein step (3) comprises the following steps:
(i) suspending each of the candidate materials in sterile buffer; and
(ii) homogenizing each of the candidate materials and then dispensing the homogenized candidate materials to the respective plates prepared in Step (2) where the feces-medium mixture was placed.
16. The method of claim 13 , wherein the toxic or undesirable substances are selected from the group consisting of hydrogen sulfide, bacterial LPS, short-chain fatty acids, and undesirable microbiota.
17. The method of claim 13 , further comprising:
(7) identifying an intestinal environment-improving material,
wherein the corresponding cultured sample results in reduced levels of toxic or undesirable substances relative to a control fecal sample not treated with a candidate an intestinal environment-improving material to screen an intestinal environment-improving material.
18. The method of claim 13 wherein the feces and the PMAS medium are mixed in a ratio of 1:12.
19. The method of claim 13 wherein the PMAS medium comprises glucose, tryptone, mucin or L-cysteine hydrochloride.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/645,451 US20230213526A9 (en) | 2019-08-30 | 2021-12-21 | Method for screening personalized intestinal environment-improving material and composition therefor |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0107146 | 2019-08-30 | ||
KR1020190107146A KR102124474B1 (en) | 2019-08-30 | 2019-08-30 | The method for Personalized Intestinal Environment Improvement Materials Screening using PMAS(Personalized Pharmaceutical Meta-Analytical Screening) method |
PCT/KR2020/001485 WO2021040159A1 (en) | 2019-08-30 | 2020-01-31 | Method for screening personalized gut environment-improving substance using pmas process |
US16/932,626 US11237172B2 (en) | 2019-08-30 | 2020-07-17 | Method for screening personalized intestinal environment-improving material and composition therefor |
US17/645,451 US20230213526A9 (en) | 2019-08-30 | 2021-12-21 | Method for screening personalized intestinal environment-improving material and composition therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/932,626 Continuation US11237172B2 (en) | 2019-08-30 | 2020-07-17 | Method for screening personalized intestinal environment-improving material and composition therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220187305A1 US20220187305A1 (en) | 2022-06-16 |
US20230213526A9 true US20230213526A9 (en) | 2023-07-06 |
Family
ID=74681728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/932,626 Active US11237172B2 (en) | 2019-08-30 | 2020-07-17 | Method for screening personalized intestinal environment-improving material and composition therefor |
US17/645,451 Pending US20230213526A9 (en) | 2019-08-30 | 2021-12-21 | Method for screening personalized intestinal environment-improving material and composition therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/932,626 Active US11237172B2 (en) | 2019-08-30 | 2020-07-17 | Method for screening personalized intestinal environment-improving material and composition therefor |
Country Status (7)
Country | Link |
---|---|
US (2) | US11237172B2 (en) |
EP (1) | EP3988664A4 (en) |
JP (1) | JP7301220B2 (en) |
CN (1) | CN114341363A (en) |
AU (1) | AU2020337596A1 (en) |
CA (1) | CA3148749A1 (en) |
MY (1) | MY197412A (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006288272A (en) * | 2005-04-11 | 2006-10-26 | Ajinomoto Co Inc | Method for obtaining microorganism by using medium containing cysteine |
FR2903574B1 (en) * | 2006-07-13 | 2008-09-05 | Gervais Danone Sa | CYSTEINE PELLETS AND THEIR USES AS BIFIDOBACTERIUM ANIMALIS LACTIS GROWTH ACTIVATORS. |
CN104206946A (en) * | 2009-11-12 | 2014-12-17 | 雀巢产品技术援助有限公司 | Nutritional composition for promoting gut microbiota balance and health |
CN106620189B (en) | 2012-06-06 | 2021-11-19 | 上海交通大学 | Method for improving intestinal flora structure and application |
PL2700715T3 (en) | 2012-08-20 | 2019-03-29 | Evonik Degussa Gmbh | Method for manufacturing L-amino acids using improved strains of the enterobacteriaceae family by means of fermentation |
CN105796541A (en) * | 2015-12-16 | 2016-07-27 | 何松庆 | Composition for treating inflammatory bowel disease |
CA3025512A1 (en) * | 2016-05-24 | 2017-11-30 | Kim SHAFER | Composition of probiotics and digestive enzymes and method of preparing and using the same |
KR101909083B1 (en) * | 2016-08-02 | 2018-10-17 | 한국과학기술연구원 | Composition for improving intestinal health comprising silymarin |
-
2020
- 2020-01-31 CN CN202080060535.1A patent/CN114341363A/en active Pending
- 2020-01-31 CA CA3148749A patent/CA3148749A1/en active Pending
- 2020-01-31 EP EP20856035.9A patent/EP3988664A4/en active Pending
- 2020-01-31 JP JP2022513541A patent/JP7301220B2/en active Active
- 2020-01-31 MY MYPI2022000433A patent/MY197412A/en unknown
- 2020-01-31 AU AU2020337596A patent/AU2020337596A1/en active Pending
- 2020-07-17 US US16/932,626 patent/US11237172B2/en active Active
-
2021
- 2021-12-21 US US17/645,451 patent/US20230213526A9/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022547435A (en) | 2022-11-14 |
CN114341363A (en) | 2022-04-12 |
EP3988664A1 (en) | 2022-04-27 |
CA3148749A1 (en) | 2021-03-04 |
AU2020337596A1 (en) | 2022-02-10 |
MY197412A (en) | 2023-06-16 |
JP7301220B2 (en) | 2023-06-30 |
US20210063407A1 (en) | 2021-03-04 |
EP3988664A4 (en) | 2023-06-21 |
US11237172B2 (en) | 2022-02-01 |
US20220187305A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Geva-Zatorsky et al. | Mining the human gut microbiota for immunomodulatory organisms | |
Harper et al. | The role of bacteria, probiotics and diet in irritable bowel syndrome | |
KR102124474B1 (en) | The method for Personalized Intestinal Environment Improvement Materials Screening using PMAS(Personalized Pharmaceutical Meta-Analytical Screening) method | |
Brahe et al. | Dietary modulation of the gut microbiota–a randomised controlled trial in obese postmenopausal women | |
Monteleone et al. | Multi-omics data integration in anorexia nervosa patients before and after weight regain: A microbiome-metabolomics investigation | |
Kang et al. | Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone | |
KR20190104914A (en) | Personalized Pharmaceutical Meta-Analytical Screening Method | |
Doré et al. | The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? | |
Karakuła-Juchnowicz et al. | Intestinal microbiota--a key to understanding the pathophysiology of anorexia nervosa? | |
Berding et al. | Dietary patterns impact temporal dynamics of fecal microbiota composition in children with autism spectrum disorder | |
Da Ros et al. | Feeding with sustainably sourdough bread has the potential to promote the healthy microbiota metabolism at the colon level | |
Ahn et al. | Effects of Lactobacillus pentosus in children with allergen-sensitized atopic dermatitis | |
US20230411013A1 (en) | Method and diagnostic apparatus for determining atopic dermatitis using machine learning model | |
Carroccio et al. | WHOLE-meal ancient wheat-based diet: Effect on metabolic parameters and microbiota | |
Nissen et al. | Sourdough process and spirulina-enrichment can mitigate the limitations of colon fermentation performances of gluten-free breads in non-celiac gut model | |
KR102227382B1 (en) | The method for personalized intestinal environment improvement materials screening using pmas(personalized pharmaceutical meta-analytical screening) method | |
US11237172B2 (en) | Method for screening personalized intestinal environment-improving material and composition therefor | |
Westreich et al. | Fecal metatranscriptomics and glycomics suggest that bovine milk oligosaccharides are fully utilized by healthy adults | |
Fukunaga et al. | Typical indigenous bacteria in the cecum of ddY mice fed a casein–beef tallow diet or whole‐egg diet | |
CN114786494A (en) | Microbiome intervention | |
Gebreselassie et al. | Anti-aging food that improves markers of health in senior dogs by modulating gut microbiota and metabolite profiles | |
US20230411012A1 (en) | Method and diagnostic apparatus for determining obesity using machine learning model | |
Schirò et al. | The Role of Human Microbiota in Myasthenia Gravis: A Narrative Review. Neurol. Int. 2023, 15, 392–404 | |
松岡翼 | Relationships between barley consumption and gut microbiome characteristics in a healthy Japanese population: a cross-sectional study | |
Almasi et al. | Role of Intestinal Microbiota in Patients with Anorexia Nervosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |